Cancer Patients Receive Nano-engineered Therapy
By Biotechdaily staff writers
Posted on 25 Jun 2004
A phase IIa clinical trial is underway in Singapore to evaluate the performance of a radioactive 32-phosphorus micro particle, called BrachySil (pSivida Ltd., Perth, Australia), in regressing otherwise inoperable liver tumors. Unlike other approaches, this microparticle is being applied directly to the tumor, where it is expected to regress the tumor with minimal damage to healthy tissues. The study is being conducted at the Singapore General Hospital.Posted on 25 Jun 2004
"This represents an important milestone, we have been working to this goal for the past two years. We hope to inform the [public] of the performance of BrachySil by the end of October 2004, reported Gavin Rezos, managing director, pSivida.
Related Links:
PSivida
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Hematology Consumables
Bioblood Devices
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
